Alfonso Tafur: Different Cancer Sites Drive Different Thrombotic Phenotypes
Alfonso Tafur, Vascular Medicine Fellowship Program Director at University of Chicago, Director of Vascular Medicine Department at NorthShore University, shared on LinkedIn:
”For years, many of us have treated cancer-associated thrombosis as if it were a single disease.
The data keep reminding us: it isn’t.
In the RIETE Registry, we looked at 18,000+ cancer patients vs. 88,000 without.
Within 90 days — 2.5× higher recurrent VTE, ~40% higher major bleeding.
But the real signal? Cancer site matters.
Lung and pancreatic drive clot risk. GI and GU drive bleeding risk.
Cancer-associated thrombosis is not one disease.
It is many biologically different thrombotic phenotypes.
Proud to be part of this team working toward precision vascular care.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026